Navigation Links
Crealta Pharmaceuticals LLC Announces Completion of the Acquisition of Substantially All of the Assets of Savient Pharmaceuticals, Inc.
Date:1/10/2014

GLENDALE, Wis., Jan. 10, 2014 /PRNewswire/ -- Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc. ("Savient"). Crealta previously announced the winning of an auction for these assets, the signing of a definitive acquisition agreement with Savient, and the subsequent approval of the transaction by the U.S. Bankruptcy Court for the District of Delaware.

The key asset acquired by Crealta is KRYSTEXXA (pegloticase), a novel biologic product that was approved by the FDA in 2010. KRYSTEXXA is a PEGylated uric acid specific enzyme, or uricase, that has been shown to statistically significantly reduce uric acid levels for many patients with refractory chronic gout.

"We are tremendously excited to have completed the transaction, and more importantly, to ensure the continued availability of this critical product," commented Ed Fiorentino, Chairman and CEO of Crealta. "Crealta is committed to providing outstanding support and service to healthcare professionals and the patients that they serve with refractory chronic gout."

Crealta was established in August 2013 in partnership with GTCR, one of the nation's leading private equity firms.

KRYSTEXXA IMPORTANT SAFETY INFORMATION

The following information is provided in both the U.S. and European prescribing information.

KRYSTEXXA is not indicated for the treatment of asymptomatic hyperuricemia. KRYSTEXXA is indicated for adults who have tried or cannot take oral gout medications and still have high uric acid levels and signs and symptoms of gout. Patients who have a genetic condition known as G6PD deficiency should not use KRYSTEXXA.

Discontinue oral urate-lowering therapies before instituting KRYSTEXXA and do not institute oral urate-lowering the
'/>"/>

SOURCE Crealta Pharmaceuticals LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Savient Reaches Agreement To Sell Substantially All Assets To Crealta Pharmaceuticals
2. Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
3. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
4. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
5. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
6. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
7. Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics
8. Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
9. Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 13
10. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
11. ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 The leading companies in ... global cardiac rhythm management device market dominate their ... Medtronic, St. Jude Medical, Boston Scientific and Asahi ... market segment. The healthcare market research publisher,s report, ... 2015 as a base year, providing forecasts for ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... 2015  The Mesothelioma Victims Center is incredibly ... get the best possible compensation, and they are also ... rare cancer caused by exposure to asbestos or ... to treatment options such as a recent possible ... Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
(Date:5/22/2015)... The American College of Traditional Chinese ... They will hold a webinar on the updates of ... on Classical Chinese Medicine. , Webinar – First Professional ... the Dean of Clinical Education, will lead this webinar ... Doctorate program. ACTCM is currently developing this degree program ...
(Date:5/22/2015)... New York, New York (PRWEB) May 22, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals ... complications due to its use continue to move ... of Louisiana. According to a Pretrial Order dated ... governing the preservation of documents and electronically stored ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning of vacation ... to help promote safe travel. , According to estimates from ... this Memorial Day weekend. Amica is sharing the following road ... , , Always wear a seatbelt: Make ... they’re driving or riding along as a passenger. Seatbelts are ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... , MONDAY, Nov. 22 (HealthDay News) -- Infants with ... at high risk for heart and lung disorders that increase their ... analyzed the medical records of more than 50,000 very low birth ... at birth. They found that among this group of babies, those ...
... current staging system that determines the extent or severity ... online in CANCER , a peer-reviewed journal of ... is no link between localized prostate cancer,s clinical stage ... his prostate removed. One of the primary purposes ...
... discovered 30 new genes that control the age of ... also act on body weight regulation or biological pathways ... Nature Genetics , was a collaborative effort by ... 104 worldwide institutions, including Boston University School of Medicine ...
... African Americans with kidney disease related to hypertension (high ... a sharply increased risk of progressive kidney disease, according ... Nephrology,s 43rd Annual Meeting and Scientific Exposition. End Stage ... African American population at a rate 13.1 times greater ...
... Kidneys ,Kidney Donations by the Poor Are on the ... low incomes are more likely to develop kidney failure and ... people of other socioeconomic classes. Because fewer individuals in the ... University of British Columbia, in Vancouver, Canada) and colleagues examined ...
... in Fruits and Vegetables ,Healthy Foods Can Help Maintain ... disease, the Western diet produces an acidic environment in the ... as kidney function declines. Nimirit Goraya, MD (Texas A&M College ... conducted a study to see if consuming a diet high ...
Cached Medicine News:Health News:Tiniest Newborns With Down Syndrome Face Other Health Risks 2Health News:Genes link puberty timing and body fat in women 2Health News:Gene linked to worsening kidney disease in African-Americans 2Health News:Efforts needed to address disparities in kidney transplantation 2Health News:Efforts needed to address disparities in kidney transplantation 3Health News:Efforts needed to address disparities in kidney transplantation 4Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 2Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 3
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Seroconversion and Antigen Panel Chart...
Medicine Products: